Covalon Technologies Ltd COV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COV is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- CAD 1.04
- Day Range
- CAD 1.10–1.11
- 52-Week Range
- CAD 0.96–2.14
- Bid/Ask
- CAD 1.10 / CAD 1.11
- Market Cap
- CAD 27.38 Mil
- Volume/Avg
- 1,700 / 5,330
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 3.61%
Company Profile
Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.covalon.com
Valuation
|
Metric
|
COV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.45 |
Price/Sales | 1.02 |
Price/Cash Flow | — |
Price/Earnings
COV
Financial Strength
|
Metric
|
COV
|
|---|---|
Quick Ratio | 3.10 |
Current Ratio | 4.81 |
Interest Coverage | — |
Quick Ratio
COV
Profitability
|
Metric
|
COV
|
|---|---|
Return on Assets (Normalized) | −16.77% |
Return on Equity (Normalized) | −21.38% |
Return on Invested Capital (Normalized) | −20.21% |
Return on Assets
COV
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hryyrssjf | Mvdy | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tgznbmhq | Lkkbxd | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Msyncpnp | Dhyfv | $107.6 Bil | |
MRNA
| Moderna Inc | Fncvdzts | Vwrx | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Ynnbdhvcm | Bds | $22.2 Bil | |
ARGX
| argenx SE ADR | Yvfjhcb | Jzwc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yghdvvpk | Sjpqsv | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xbtfwpyy | Jqmxhb | $15.1 Bil | |
INCY
| Incyte Corp | Trvhwlft | Wmlqyp | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nvqmgfxy | Drtwhm | $12.7 Bil |